Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.

Ottaviani D, Ola M, Allotta A, Maati Chaibi Y, Hickey S, Jagust P, Cosgrove N, Cocchiglia S, Bane F, Fallon R, Daly G, Hegarty A, Hudson L, Sheehan K, Kalsi S, Shovlin S, Powell A, Bahl A, Ainscow E, Oesterreich S, Lee AV, Couch FJ, Hill ADK, Varešlija D, Young L

Open source

DOI: 10.1093/jnci/djaf295
Published: 2026 Mar 1
Container: Journal of the National Cancer Institute
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jnci/djaf295,
  title = {Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.},
  author = {Ottaviani D and Ola M and Allotta A and Maati Chaibi Y and Hickey S and Jagust P and Cosgrove N and Cocchiglia S and Bane F and Fallon R and Daly G and Hegarty A and Hudson L and Sheehan K and Kalsi S and Shovlin S and Powell A and Bahl A and Ainscow E and Oesterreich S and Lee AV and Couch FJ and Hill ADK and Varešlija D and Young L},
  year = {2026},
  journal = {Journal of the National Cancer Institute},
  doi = {10.1093/jnci/djaf295},
  url = {https://doi.org/10.1093/jnci/djaf295}
}

RIS

TY  - JOUR
TI  - Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
AU  - Ottaviani D
AU  - Ola M
AU  - Allotta A
AU  - Maati Chaibi Y
AU  - Hickey S
AU  - Jagust P
AU  - Cosgrove N
AU  - Cocchiglia S
AU  - Bane F
AU  - Fallon R
AU  - Daly G
AU  - Hegarty A
AU  - Hudson L
AU  - Sheehan K
AU  - Kalsi S
AU  - Shovlin S
AU  - Powell A
AU  - Bahl A
AU  - Ainscow E
AU  - Oesterreich S
AU  - Lee AV
AU  - Couch FJ
AU  - Hill ADK
AU  - Varešlija D
AU  - Young L
PY  - 2026
JO  - Journal of the National Cancer Institute
DO  - 10.1093/jnci/djaf295
UR  - https://doi.org/10.1093/jnci/djaf295
ER  -

APA

D, O., M, O., A, A., Y, M. C., S, H., P, J., N, C., S, C., F, B., R, F., G, D., A, H., L, H., K, S., S, K., S, S., A, P., A, B., E, A., S, O., AV, L., FJ, C., ADK, H., D, V., & L, Y. (2026). Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf295

Source records

pubmed · retrieved 2026-09-27T01:30:57.261Z